Trial
NCT03353220
Predictors of Lorcaserin-Induced Weight Loss
Phase IVTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Columbia University
Collaborators
New York State Psychiatric Institute; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Condition
Overweight and Obesity
Intervention
Belviq
Why stopped
The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-27